GeneDx (WGS) announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer, CGO, and Jennifer Brendel as Chief of Corporate Affairs, CCA. Both executives will report to Katherine Stueland, CEO and President, and will collaborate in continuing to strengthen GeneDx’s market leading position in genomic interpretation and health insights. Bringing nearly 20 years of genomic industry experience, in her role as Chief Growth Officer, Duquette will be responsible for the company’s overall growth strategy and will lead the sales, market access, clinician marketing and client services functions. Duquette joins GeneDx from Invitae (NVTA) where she most recently served as the Head of US Sales for Invitae. In her previous position as Chief Commercial Officer for GeneDx, Jen Brendel set the foundation of the commercial footprint and strategy for the Company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WGS:
- GeneDx sequences over 500,000 clinical exomes
- GeneDx announces data on whole exome, genome sequencing report fewer VUS
- GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
- GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GeneDx reports Q2 EPS ($1.84), consensus ($1.31)